Literature DB >> 27080373

Etiology and medical management of NEC.

Amit Gupta1, Anshuman Paria2.   

Abstract

Necrotising enterocolitis (NEC) is a serious infection of the bowel that predominantly affects preterm infants and is a leading cause for mortality and morbidity in preterm infants. It involves a spectrum of pathology including widespread inflammation of the intestinal mucosa, invasion of the immature gut by enteric gas forming bacteria, dissection of the gut wall and portal veins by this gas, often culminating in ischemic necrosis of the intestine. This article provides an overview of the incidence, etio-pathological risk factors, preventive strategies and medical management of NEC.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bells classification; Dysbiosis; Human milk; Necrotising enterocolitis; Probiotics; Toll like receptors; Transfusion

Mesh:

Year:  2016        PMID: 27080373     DOI: 10.1016/j.earlhumdev.2016.03.008

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  12 in total

Review 1.  Standardized feeding regimen for reducing necrotizing enterocolitis in preterm infants: an updated systematic review.

Authors:  B Jasani; S Patole
Journal:  J Perinatol       Date:  2017-03-30       Impact factor: 2.521

2.  Association of single nucleotide polymorphisms of IL23R and IL17 with necrotizing enterocolitis in premature infants.

Authors:  Jiayi Tian; Yanjun Liu; Yanfang Jiang; Haohan Zhou; Tong Zhu; Xiaoqi Zhao; Liping Peng; Chaoying Yan
Journal:  Mol Cell Biochem       Date:  2017-02-21       Impact factor: 3.396

3.  The miR-223/nuclear factor I-A axis regulates inflammation and cellular functions in intestinal tissues with necrotizing enterocolitis.

Authors:  Yu Zheng Wu; Kathy Yuen Yee Chan; Kam Tong Leung; Hugh Simon Lam; Yuk Him Tam; Kim Hung Lee; Karen Li; Pak Cheung Ng
Journal:  FEBS Open Bio       Date:  2021-06-01       Impact factor: 2.693

Review 4.  The Significance of the Enteric Microbiome on the Development of Childhood Disease: A Review of Prebiotic and Probiotic Therapies in Disorders of Childhood.

Authors:  John Slattery; Derrick F MacFabe; Richard E Frye
Journal:  Clin Med Insights Pediatr       Date:  2016-10-09

5.  Neonatal Perforated Appendicitis Masquerading as Necrotizing Enterocolitis.

Authors:  Andrew Tumen; Pranit N Chotai; John Matthew Williams; Adrianne Myers-Webb; Jie Zhang; Ramesh Krishnan; James W Eubanks Iii
Journal:  J Neonatal Surg       Date:  2017-04-15

6.  Neonatal Perforated Appendicitis Attributed to Localized Necrotizing Enterocolitis of the Appendix: A Review.

Authors:  Andrew Tumen; Pranit N Chotai; John Matthew Williams; Adrianne Myers-Webb; Ramesh Krishnan; James W Eubanks Iii
Journal:  J Neonatal Surg       Date:  2017-08-10

Review 7.  Recent Potential Noninvasive Biomarkers in Necrotizing Enterocolitis.

Authors:  Kewei Wang; Guozhong Tao; Zhen Sun; Karl G Sylvester
Journal:  Gastroenterol Res Pract       Date:  2019-04-22       Impact factor: 2.260

Review 8.  It's all in the milk: chondroitin sulfate as potential preventative therapy for necrotizing enterocolitis.

Authors:  Thomas A Knowles; Brian D Hosfield; Anthony R Pecoraro; Hongge Li; W Christopher Shelley; Troy A Markel
Journal:  Pediatr Res       Date:  2020-09-13       Impact factor: 3.953

9.  Developmental 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure of either parent enhances the risk of necrotizing enterocolitis in neonatal mice.

Authors:  Shilpa Mokshagundam; Tianbing Ding; Jelonia T Rumph; Madison Dallas; Victoria R Stephens; Kevin G Osteen; Kaylon L Bruner-Tran
Journal:  Birth Defects Res       Date:  2020-06-09       Impact factor: 2.661

10.  Lactobacillus murinus HF12 colonizes neonatal gut and protects rats from necrotizing enterocolitis.

Authors:  Mubina Isani; Brandon A Bell; Patrick T Delaplain; Jordan D Bowling; Jamie M Golden; Melissa Elizee; Laura Illingworth; Jin Wang; Christopher P Gayer; Anatoly V Grishin; Henri R Ford
Journal:  PLoS One       Date:  2018-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.